Bordetella bronchiseptica is a Gram-negative coccobacillus that frequently causes infections in animals, including atrophic rhinitis in swine, snuffles in rabbits and kennel cough in dogs. 1 The most common symptom of kennel cough is a dry 'honking' cough. B. bronchiseptica belongs to the same genus as the causative agent of whooping cough in humans, Bordetella pertussis, an organism that infects only humans. Most infections with B. bronchiseptica occur in immunocompromised individuals exposed to farm or companion animals, although infections have been reported in immunocompetent patients. [1] [2] [3] The organism is usually susceptible in vitro to the aminoglycosides, antipseudomonal penicillins, quinolones, tetracycline, thirdgeneration cephalosporins and trimethoprim-sulfamethoxazole. Effective treatment is often difficult because of the patient's underlying disease and the ability of the organism to invade and persist in epithelial cells. The two veterinary vaccines currently marketed are an avirulent live intranasal vaccine and a s.c. antigen extract vaccine. Although data suggest that the intranasal route may be effective within 72 h, there is less data on the efficacy of the s.c. vaccine.
We present a case of B. bronchiseptica infection in a patient with graft-versus-host disease (GVHD) after allogeneic hematopoietic SCT (allo-HSCT). A 29-year-old man with chemorefractory stage IIIB anaplastic large celllymphoma underwent a myeloablative conventional allo-HSCT from a 10/10 matched unrelated donor after conditioning with TBI, thiotepa and CY. He received tacrolimus, sirolimus and MTX for GVHD prophylaxis. His transplant course was notable for acute renal failure and the nephrotic syndrome with a maximum creatinine of 3.5 mg/dl, which resolved after the discontinuation of sirolimus. Grade III gut GVHD was diagnosed by sigmoidoscopy on day þ 90 and he was treated with steroids (max dose 2 mg/kg), in addition to the ongoing tacrolimus and mycophenolate mofetil (MMF). On approximately day þ 170 he developed a flare of his gut GVHD while completing a slow taper of his prednisone necessitating an increase in steroid doses. On day þ 202, he first reported a persistent productive cough. He also noted dyspnea with exertion, but no fevers. Azithromycin was prescribed without relief in symptoms. Subsequently, he reported that his four-month-old puppy had been diagnosed with kennel cough approximately 2-3 weeks before the start of his symptoms. The dog had received one dose of the s.c vaccine, BronchicinetCAe, without subsequent booster. After presenting to the veterinarian with the classic honking cough and rhinorrhea, the dog was empirically treated with an antibiotic injection leading to a rapid improvement in her symptoms. A nasopharyngeal specimen from the patient was sent for culture, with a specific request to rule out B. bronchiseptica. The culture was positive for B. bronchiseptica, sensitive to the usual antibiotics. He was treated with levofloxacin with an improvement in his symptoms. On completion of the antibiotics, he had recurrent symptoms and his culture showed the persistence of B. bronchiseptica. He was treated with a second course of levofloxacin. His chest X-Ray did not show any evidence of pneumonia and his symptoms improved again. A third nasopharyngeal specimen, collected three weeks later, was also culture-positive for B. bronchiseptica. He was then treated with a course of ciprofloxacin and doxycycline, on the basis of antimicrobial susceptibility test results. While on this therapy, a repeat specimen was culture-positive for B. bronchiseptica, now with resistance to ciprofloxacin. As he continued to report a slight chronic cough, his treatment was changed to inhaled tobramycin, and after four weeks of treatment, his nasopharyngeal specimens remained culture positive. He was observed off therapy and, because his symptoms had resolved by this time, he did not receive further antibiotics. In total, he received 10 weeks of antibiotic therapy.
Despite the widespread prevalence and infection in the animal community, B. bronchiseptica infections in humans are relatively rare, with the majority of cases involving patients who were immunocompromised. The prevalence of human infection has been increasing, possibly as a result of the AIDS epidemic 4 and an increased number of organ transplants. Four earlier cases of human infection with B. bronchiseptica have been reported in patients after allo-HSCT (Table 1) . The first two cases may represent transmission from dogs to humans. 5, 6 The two more-recent cases suggest nosocomial transmission as the two were described within three days of each other in the same institution. 7 These patients were frequently seen for followup in the same clinic space, and pulsed-field gel electrophoresis analysis showed that the patients were infected with the same strain.
Our case suggests transmission of B. bronchiseptica in a symptomatic puppy to a post transplant patient with GVHD with continued colonization after multiple courses of antibiotics. This case, in addition to the four earlier reported cases of B. bronchiseptica infections in allo-HSCT recipients, has significant implications for the counseling we provide our transplant patients. We need to continue to be diligent and advise our patients to not only avoid sick humans but also avoid animal contact, especially with sick animals and young animals who may have received live vaccines. Further, we need to carefully inquire about pet exposures when our post transplant patients fall ill. 
